BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34538873)

  • 21. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
    Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
    Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?
    Trpkov K; Williamson SR; Gao Y; Martinek P; Cheng L; Sangoi AR; Yilmaz A; Wang C; San Miguel Fraile P; Perez Montiel DM; Bulimbasić S; Rogala J; Hes O
    Histopathology; 2019 Aug; 75(2):174-184. PubMed ID: 30895640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity.
    Williamson SR; Hes O; Trpkov K; Aggarwal A; Satapathy A; Mishra S; Sharma S; Sangoi A; Cheng L; Akgul M; Idrees M; Levin A; Sadasivan S; San Miguel Fraile P; Rogala J; Comperat E; Berney DM; Bulimbasic S; McKenney JK; Jha S; Sampat NY; Mohanty SK
    Histopathology; 2023 Jan; 82(2):296-304. PubMed ID: 36208048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
    Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
    Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China.
    Guo Q; Liu N; Wang F; Guo Y; Yang B; Cao Z; Wang Y; Wang Y; Zhang W; Huang Q; Zhao W; Liu C; Qu T; Li L; Cao L; Ren D; Meng B; Qi L; Wang C; Cao W
    Virchows Arch; 2021 Mar; 478(3):449-458. PubMed ID: 32918598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.
    He H; Trpkov K; Martinek P; Isikci OT; Maggi-Galuzzi C; Alaghehbandan R; Gill AJ; Tretiakova M; Lopez JI; Williamson SR; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Pivovarcikova K; Michalova K; Slouka D; Prochazkova K; Hora M; Bonert M; Michal M; Hes O
    Virchows Arch; 2018 Dec; 473(6):725-738. PubMed ID: 30232607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.
    Foix MP; Dunatov A; Martinek P; Mundó EC; Suster S; Sperga M; Lopez JI; Ulamec M; Bulimbasic S; Montiel DP; Alaghehbandan R; Peckova K; Pivovarcikova K; Ondrej D; Rotterova P; Skenderi F; Prochazkova K; Dusek M; Hora M; Michal M; Hes O
    Virchows Arch; 2016 Dec; 469(6):669-678. PubMed ID: 27631338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-Grade Oncocytic Tumor: Report of Two Cases of An Emerging Entity in the Spectrum of Oncocytic Renal Neoplasms.
    Sharma D; Pai T; Prakash G; Desai S; Menon S
    Turk Patoloji Derg; 2022; 38(2):162-166. PubMed ID: 34514579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway.
    Mohanty SK; Satapathy A; Aggarwal A; Mishra SK; Sampat NY; Sharma S; Williamson SR
    Mod Pathol; 2022 Mar; 35(3):361-375. PubMed ID: 34802045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics.
    Kravtsov O; Gupta S; Cheville JC; Sukov WR; Rowsey R; Herrera-Hernandez LP; Lohse CM; Knudson R; Leibovich BC; Jimenez RE
    Hum Pathol; 2021 Aug; 114():9-18. PubMed ID: 33961838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case.
    Pires-Luis A; Montezuma D; Vieira J; Ramalho-Carvalho J; Santos C; Teixeira M; Jerónimo C; Henrique R
    Exp Mol Pathol; 2018 Dec; 105(3):352-356. PubMed ID: 30343009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Eosinophilic, solid, and cystic renal cell carcinoma (ESC-RCC)].
    Hartmann A; Agaimy A
    Pathologe; 2021 Nov; 42(6):565-570. PubMed ID: 34550432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex.
    Lerma LA; Schade GR; Tretiakova MS
    Hum Pathol; 2021 Oct; 116():1-11. PubMed ID: 34153307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features.
    Xia QY; Rao Q; Shen Q; Shi SS; Li L; Liu B; Zhang J; Wang YF; Shi QL; Wang JD; Ma HH; Lu ZF; Yu B; Zhang RS; Zhou XJ
    Int J Clin Exp Pathol; 2013; 6(7):1392-9. PubMed ID: 23826421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fine-needle aspiration biopsy of chromophobe renal cell carcinoma and oncocytoma: comparison of cytomorphologic features.
    Wiatrowska BA; Zakowski MF
    Cancer; 1999 Jun; 87(3):161-7. PubMed ID: 10385448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
    Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
    Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinicopathological features of hybrid oncocytic/chromophobe renal cell tumor].
    Wang Y; Chong DC; Xin FJ; He B; Liu XL; Li YJ; Zhang W; Jiang YX
    Zhonghua Bing Li Xue Za Zhi; 2021 Feb; 50(2):97-102. PubMed ID: 33535302
    [No Abstract]   [Full Text] [Related]  

  • 38. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
    Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
    J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LOT and HOT … or not. The proliferation of clinically insignificant and poorly characterised types of renal neoplasia.
    Samaratunga H; Egevad L; Thunders M; Iczskowski KA; van der Kwast T; Kristiansen G; Pan CC; Leite KRM; Evans A; Clouston D; Kenwright DN; Bethwaite PB; Malone G; Wood S; Yaxley JW; Delahunt B
    Pathology; 2022 Dec; 54(7):842-847. PubMed ID: 36270849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomorphology, immunoprofile, and management of renal oncocytic neoplasms.
    Zhu B; Rohan SM; Lin X
    Cancer Cytopathol; 2020 Dec; 128(12):962-970. PubMed ID: 32697415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.